Definium Therapeutics, Inc. financial data

Symbol
DFTX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 522% % -14%
Debt-to-equity 40% % 36%
Return On Equity -84% % -75%
Return On Assets -60% % -62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99,698,129 shares 32%
Common Stock, Shares, Outstanding 98,776,265 shares 32%
Entity Public Float $487,700,000 USD -5.4%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 89,327,608 shares 27%
Weighted Average Number of Shares Outstanding, Diluted 89,327,608 shares 27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $117,665,000 USD 80%
General and Administrative Expense $48,644,000 USD 26%
Operating Income (Loss) $166,309,000 USD -60%
Net Income (Loss) Attributable to Parent $183,793,000 USD -69%
Earnings Per Share, Basic -2.06 USD/shares -34%
Earnings Per Share, Diluted -2.06 USD/shares -34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $257,837,000 USD -5.8%
Assets, Current $419,320,000 USD 49%
Operating Lease, Right-of-Use Asset $600,000 USD
Goodwill $19,918,000 USD 0%
Other Assets, Noncurrent $862,000 USD 41%
Assets $440,100,000 USD 46%
Accounts Payable, Current $5,347,000 USD 166%
Accrued Liabilities, Current $20,446,000 USD 59%
Liabilities, Current $66,698,000 USD 72%
Other Liabilities, Noncurrent $496,000 USD
Liabilities $107,773,000 USD 78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,085,000 USD 32%
Retained Earnings (Accumulated Deficit) $582,672,000 USD -46%
Stockholders' Equity Attributable to Parent $332,327,000 USD 38%
Liabilities and Equity $440,100,000 USD 46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $29,419,000 USD -77%
Net Cash Provided by (Used in) Financing Activities $1,002,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares, Issued 98,776,265 shares 32%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $190,887,000 USD -225%
Interest Paid, Excluding Capitalized Interest, Operating Activities $602,000 USD 39%
Deferred Tax Assets, Valuation Allowance $109,684,000 USD 57%
Operating Lease, Liability $600,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $183,527,000 USD -70%
Deferred Tax Assets, Operating Loss Carryforwards $78,395,000 USD 85%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $900,000 USD
Amortization of Intangible Assets $0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance $118,000 USD
Share-based Payment Arrangement, Expense $20,096,000 USD 19%
Interest Expense $5,482,000 USD 140%